Benefit with methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis: study of 11 cases in 11 years.
Primary progressive multiple sclerosis (PPMS) is defined clinically with a progressive course from onset. There is no approved treatment for the PPMS. Methylprednisolone IV (MP) hastens the recovery from MS relapses. We studied 11 patients that met the MacDonald's diagnostic criteria for PPMS. The dose of MP was 30 mg/kg in 250 mL of glucose solution in three consecutive days during the first week, two doses during the second and one dose in the third week. One weekly session for eight consecutive weeks was given. After, a once-a week/eight-week interval was maintained. The medium EDSS before treatment was 6.2, and after 11.2 years of treatment, the EDSS was 4.9. Although we studied a small sample of PPMS we may conclude that therapy with IVMP prevents clinical worsening of MS in the majority of patients with improvement in EDSS scores.
Araújo
Edmar A S de
EA
Neuroimmunoly Unit, Neurological Service, Hospital Universitário Antonio Pedro, Universidade Federal Fluminense, Niterói, RJ, Brazil. edmardearaujo2@yahoo.com.br
Freitas
Marcos R Gomes de
MR
D000328:Adult; D017677:Age Distribution; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D004304:Dosage Forms; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000175:diagnosis / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D017678:Sex Distribution; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D004304:Dosage Forms; D018696:Neuroprotective Agents; D008775:Methylprednisolone